Prospective studies of serum hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C are lacking. The aim of this study was to determine the frequencies and performance of elevated α -fetoprotein (AFP), AFP-L3, and des-γ -carboxy prothrombin (DCP) levels as HCC biomarkers in advanced hepatitis C.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide, and its incidence in the United States has more than doubled in the past 25 years ( 1 ), principally a consequence of hepatitis C virus (HCV) infection ( 2 ) . Th e 5-year survival rate of patients with HCC is < 10 % ( 1 ), because of late detection and lack of treatment options for patients with advanced-stage disease. Detection of early HCC (single nodule < 2 cm) at a stage of disease amenable to treatment (liver transplantation, surgical resection, chemoembolization, or percutaneous ablation) ( 3, 4 ) ( 5 -9 ) and serum biomarkers. Th e α -fetoprotein (AFP) is the most commonly used biomarker, but its sensitivity and specifi city in detecting HCC is poor. AFP levels are oft en increased as oft en in people with cirrhosis without HCC as in patients with HCC ( 10 -12 ) . Accordingly, the AASLD (American Association for the Study of Liver Diseases) Practice Guidelines Committee recommended the use of ultrasound alone, without AFP , for HCC surveillance in patients with cirrhosis ( 13 ) .
Other tumor biomarkers have been proposed to complement or substitute for AFP in HCC detection ( 14, 15 ) . Th e two biomarkers currently used clinically are Lens culinaris agglutinin (LCA)-reactive fraction of α -fetoprotein (AFP-L3) ( 16 -19 ) and des-γ -carboxy prothrombin (DCP), an abnormal prothrombin molecule that is generated as a result of an acquired defect in the posttranslational carboxylation of the prothrombin precursor in malignant cells ( 20 -27 ) . Th ese tumor markers have been adopted routinely in Japan since the late 1990s, but few prospective studies evaluating their usefulness in North American populations have been performed ( 28 ) . Because AFP and DCP represent independent tumor proteins, several studies have shown that they may be complementary in the detection of HCC ( 29 -32 ) .
Few studies have involved cohorts of at-risk people followed prospectively to determine and compare the frequency of elevated biomarkers among those in whom HCC did and did not develop. In the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial, patients with chronic hepatitis C and bridging fi brosis or cirrhosis were followed prospectively, allowing us to examine the relationships of serum biomarkers to incidence of HCC. In a previous nested case -control study that included 39 HCC cases and 77 matched controls, we focused on the performance of biomarkers in the diagnosis of HCC ( 32 ) . In the current analysis, we measured AFP, AFP-L3, and DCP serially and determined the frequency and factors associated with elevated HCC biomarkers (AFP, AFP-L3, and DCP) and their test characteristics (sensitivity, specifi city, predictive value, and area under the receiver operating characteristic curve (ROC) in all HALT-C subjects with and without HCC.
METHODS

HALT-C trial design, HCC defi nition, and surveillance
Th e HALT-C Trial was a multicenter, prospective study conducted at 10 clinical sites on the safety and effi cacy of half-dose, longterm maintenance peginterferon treatment in patients with histologically advanced hepatitis C ( 33 ). Inclusion criteria were age ≥ 18 years, chronic hepatitis C with advanced fi brosis (Ishak fi brosis score ≥ 3), nonresponse to prior interferon ± ribavirin treatment, and absence of laboratory markers or clinical events associated with hepatic decompensation. All patients were required to have an ultrasound, computed tomography, or magnetic resonance imaging with no evidence of hepatic mass lesions suspicious for HCC and a serum AFP < 200 ng / ml before enrollment (protocol exceptions were allowed for three patients who had AFP values of 206, 212, and 315 ng / ml, respectively, and negative imaging).
Patients in whom HCV RNA remained detectable aft er 20 weeks of lead-in treatment with peginterferon alfa-2a, 180 μ g weekly, and ribavirin, 1,000 / 1,200 mg / day, were randomized at week 24 to either no treatment (control group) or to continue peginterferon alfa-2a (Pegasys, Genentech, USA) monotherapy at a dose of 90 μ g weekly (treatment group). Patients were seen every 3 months through month 48 of the randomized trial to assess for clinical end points and adverse events. Blood samples were collected at each visit and tested for AFP immediately aft er the visit at the clinical laboratory of each participating hospital. For this study, in contrast to our prior report ( 34 ) , frozen serum samples collected at each visit through month 48 (42 months aft er randomization) were tested for all biomarkers, (AFP, AFPL3, and DCP) at a central laboratory (Wako Laboratories, Richmond, VA) in all patients. Results of these assays were not available to investigators during the trial. Perprotocol ultrasound examinations of the liver were repeated 6 and 12 months aft er enrollment and again every 12 months. Patients with an elevated or rising AFP by local laboratory and those with new lesions on ultrasound were evaluated further by computed tomography or magnetic resonance imaging, at the discretion of the site investigator. Aft er month 48, patients were tested for AFP at the local laboratory and ultrasounds were performed at 6-month intervals but blood samples were not sent to the central laboratory for testing of AFP, AFPL3, and DCP; therefore, only patients diagnosed to have HCC by month 60 were included in this analysis.
HCC was defi ned as previously described in the HALT-C Trial ( 34 ). Defi nite HCC was defi ned by histologic confi rmation or by the appearance of a new mass lesion on imaging with AFP levels increasing to ≥ 1,000 ng / ml. Presumed HCC was defi ned by the appearance of a new mass lesion on ultrasound in the absence of histology and with AFP < 1,000 ng / ml in conjunction with one of the following: (i) two liver imaging studies showing a mass lesion with characteristics of HCC (arterial enhancement ± washout), (ii) progressively enlarging lesion(s) on ultrasound leading to death, or (iii) one additional imaging study showing a mass lesion with characteristics of HCC that either increased in size over time or was accompanied by an AFP level rising to > 200 ng / ml and more than a tripling of the baseline value. All cases of HCC were adjudicated by an Outcomes Review Panel, blinded to study site and randomization allocation, to ascertain that cases met predefi ned diagnostic criteria and to determine the date when these criteria were fi rst met. Th e radiology reports of all HCC cases were reviewed retrospectively by the HCC working group to determine the date when the last imaging showed no hepatic lesion, the date when imaging fi rst revealed a suspicious nodule, and the tumor stage at diagnosis. Th is analysis focused on patients without HCC (defi nite or presumed) at any time during the HALT-C Trial, and we included HCC cases diagnosed through month 60 (12 months aft er last biomarker evaluation) for comparison.
Defi nition of biomarker cutoff values and time periods
For AFP, we defi ned three " absolute " cutoff values and one " relative " cutoff value. Th e absolute cutoff values were an AFP ≥ 20, ≥ 50, or ≥ 200 ng / ml. Th e relative AFP cutoff value had to meet the following two criteria: (i) AFP ≥ 20 ng / ml and (ii) AFP value more than twice the average AFP values during the prior 12-month period. For DCP, we also defi ned three absolute cutoff values ( ≥ 40, ≥ 90, and ≥ 150 mAU / ml) and one relative cutoff value. We chose 90 mAU / ml as the middle cutoff value, because prior analysis of the HALT-C Trial data had suggested that a DCP cutoff of 87 mAU / ml had the best test performance in diff erentiating HCC cases from controls ( 34 ) . Th e relative DCP cutoff value had to meet the following two criteria: (i) DCP ≥ 40 and (ii) DCP value more than twice the average DCP values during the prior 12-month period (see below for time periods). An AFP-L3 ≥ 10 % was considered abnormal as per the manufacturer.
We divided the fi rst 60 months of the HALT-C study into consecutive 12-month time periods (months 1 -12, 13 -24, 25 -36, 37 -48, and 49 -60) to account for the variable time periods that patients were followed. Results in the fi rst 12-month period were not included in this analysis, because randomization occurred at month 6, and patients who met the criteria for HCC in the fi rst 6 months would not have been randomized. In addition, fulldose peginterferon and ribavirin treatment had been shown to decrease AFP levels ( 12 ) . According to the study protocol, patients should have had biomarker levels assessed four times during each 12-month period. For the purposes of these analyses, we used the highest value for each biomarker during the 12-month period, and for HCC cases, we used only the biomarker values up to the HALT-C Trial visit immediately before the diagnosis of HCC. Also, to be included in this analysis, patients had to be followed for at least 6 months aft er randomization, had to have at least one visit in the fi rst 18 months aft er randomization, and, if they had an AFP or DCP elevation, had to be followed for at least 1 year aft er the fi rst elevation. In assessing the occurrence of HCC, we determined the number of patients in whom presumed or defi nite HCC was identifi ed during the same 12-month time period as the biomarker was drawn and the number of patients in whom HCC was identifi ed during the subsequent 12-month time period. Th us, for our determination of the sensitivity and specifi city of the biomarkers, the interval between the biomarker testing and the diagnosis of HCC ranged from 0 to 24 months.
Statistical analyses
Statistical analyses were performed at the Data Coordinating Center with SAS release 9.1 (SAS Institute, Cary, NC). All reported P values are two sided. We used Cox proportional hazards regression to assess the relationship between baseline characteristics and elevated AFP or DCP during months 13 to 48 and logistic regression to assess the association between patient characteristics and elevations in AFP or DCP during a 12-month period. For this analysis, we used clinical and laboratory data at months 12, 24, or 36 to predict the likelihood of AFP or DCP elevation during months 13 -24, 25 -36, and 37 -48, respectively. To determine the accuracy of biomarker elevations in predicting the diagnosis of HCC during the same time period or the next 12 months, we classifi ed HCC cases into four groups according to the date of the last study visit before the diagnosis of HCC: months 13 -24, 25 -36, 37 -48, and 49 -60. Sensitivity, specifi city, positive and negative predictive values, area under the ROC curve, and P value from a logistic regression were calculated to evaluate the association between an elevated biomarker during a given 12-month period and the development of HCC in that time period or the next 12-month period. For this analysis, patients in whom HCC developed more than a year aft er the end of the current study period (i.e., aft er month 60) were excluded. Because we previously reported that increased AFP can be seen in the absence of HCC ( 12 ) , and that HCC can occur in the absence of cirrhosis ( 34 ), we included all patients with advanced fi brosis rather than just those with cirrhosis.
RESULTS
Baseline characteristics of the patients
A total of 1,050 patients were randomized in the HALT-C Trial. Of these, 54 met criteria for defi nite or presumed HCC by month 60. Eight HCC cases were excluded from these analyses for one of the following reasons: (i) prevalent HCC, defi ned as HCC diagnosed within 6 months aft er randomization ( n = 4), (ii) missing laboratory data before diagnosis ( n = 2), and (iii) patients with a diagnosis of presumed HCC who did not receive treatment for HCC and were followed for at least 24 months with no evidence of radiologic or clinical progression of their liver nodules ( n = 2). An additional 187 patients without HCC by month 60 were excluded because they were followed for < 6 months aft er randomization ( n = 41), missed all visits in the fi rst 18 months aft er randomization ( n = 40), were taking Coumadin, which can markedly elevate DCP in the absence of HCC by inhibiting vitamin k coagulation ( n = 11), did not have an AFP or DCP value 1 year aft er their fi rst AFP or DCP elevation ( n = 59), or had HCC between month 60 and end of the study ( n = 36). In total, 46 patients with HCC diagnosed by month 60 and 809 patients without HCC at any time during the course of the HALT-C Trial were included in this analysis. Th e baseline characteristics of the patients with and without at least one elevated AFP and / or DCP during months 13 to 48 are shown in Table 1 . Th ose with total AFP ≥ 20 ng / dl on ≥ 1 occasion during months 13 to 48 were less likely male, less likely nonHispanic white, with higher values of body mass index, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase, and more advanced disease (lower platelet count, higher AST -platelet ratio index, model for end-stage liver disease, and cirrhosis) compared with those with total AFP persistently < 20 ng / dl. In those with elevated AFP, HCC was also more likely to develop (10 % vs. 3 % ; P < 0.0001). No diff erences were apparent in mean baseline DCP values between those with AFP < 20 or ≥ 20 ng / ml. Conversely, those with DCP ≥ 90 mAU / ml were more likely male and had higher total AFP compared with those with DCP < 90 mAU / ml. Similarly, in subjects with elevated DCP, liver disease was more advanced and HCC was more likely to develop (11 % vs. 3 % ; P < 0.0001). Table 2 shows the frequency of elevated AFP, DCP, and AFP-L3 levels during the entire 36 months of the study (months 13 -48) for all patients. Th e average number of measurements per patient LIVER HCC Biomarker was 10.5 (out of a possible 12), with 80 % having > 9 measurements. Overall, a higher percentage of patients had elevated DCP than elevated AFP values.
Frequency of AFP, AFP-L3, and DCP elevations
Of the 855 patients tested during months 13 -48, 28.3, 13.0, and 3.0 % had peak AFP values ≥ 20, ≥ 50, and ≥ 200 ng / ml, respectively, whereas 70.5, 28.0, and 16.1 % had peak DCP values ≥ 40, ≥ 90, and ≥ 150 mAU / ml, respectively. When biomarker elevation was defi ned based not only on absolute values but also on an increase to ≥ 2-fold the mean value in the previous year, 16.8 % of patients had peak AFP ≥ 20 ng / ml and ≥ 2 fold the mean value in the previous year, whereas 25.0 % of patients had peak DCP ≥ 90 mAU / ml and ≥ 2 fold the mean value in the previous year. Contrary to the high frequency of elevated AFP or DCP values, only 9.6 % of all patients regardless of total AFP levels had AFP-L3 ≥ 10 % . Analysis of the combination of these biomarkers showed that 10.9 % had peak AFP ≥ 20 ng / ml and peak DCP ≥ 90 U / ml, 4.4 % had elevated total AFP and AFP-L3 % values, and only 3.0 % had peak AFP ≥ 20 ng / ml, peak DCP ≥ 90 U / ml, and peak AFP-L3 ≥ 10 % .
Factors associated with AFP or DCP elevations
To determine baseline demographic and laboratory factors associated with AFP or DCP elevations, we compared patients with AFP ≥ 20 ng / ml on at least one occasion during each time period to the patients who had AFP persistently < 20 ng / ml, and Cox proportional hazards regression comparing those with DCP < 90 and ≥ 90 mAU / ml. c Patients randomized to long-term treatment with peginterferon alfa-2a monotherapy at a dose of 90 μ g weekly.
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and HCC during that time period or the following time period (i.e., months 37 -60). Logistic regression analysis revealed that DCP elevation during months 37 -48 was associated independently with non-Black ethnicity, randomization to peginterferon, low albumin at month 36, high prothrombin time / international normalized ratio at month 36, and HCC during that time period or the subsequent time period. Similar associations were noted when regression analyses were performed to determine predictors of elevated AFP or DCP during months 13 -24 and months 25 -36, except that a diagnosis of HCC at months 13 -36 was not associated with biomarker elevations at months 13 -24 (data available in Supplementary Table A online).
Biomarker elevation in patients with and without HCC
Th e frequency of elevated biomarkers at any time between months 13 and 48 during a mean study period of 34 months for patients without HCC and 27 months for HCC cases and a mean number of 11 tests for patients without HCC and 7 for HCC cases are shown in Figure 1 . Although the frequency of biomarker elevation was more common in those with HCC, importantly, biomarker elevation was also common in those without HCC. In all, 53 % of patients without HCC and 22 % of HCC cases had no biomarker elevations throughout the study. Only 17.1 % of those without HCC and with total AFP values > 20 ng / dl had increased levels of AFP-L3 % . Th erefore, the negative predictive value for AFP-L3 in those with elevated total AFP ≥ 20 ng / ml was 92 % .
To control for the eff ect of varying durations of follow-up, we analyzed the percentage of patients who met HALT-C Trial criteria for HCC during the same time period and during the subsequent 12 months. When biomarker elevations at months we compared patients with DCP ≥ 90 mAU / ml on at least one occasion during each time period to the patients who had DCP persistently < 90 mAU / ml during the same time period ( Table 3 ) . Multivariate logistic regression analysis showed that AFP elevation during months 37 -48 was associated independently with female gender, Black ethnicity, a low platelet count at month 36, high AST at month 36, high alkaline phosphatase at month 36, Table 2 Percentage of patients, cases and controls combined, with a biomarker above the specifi ed limits at any one of the 12 study visits from month 13 to month 48 (0.5 -3.5 years after randomization). 
Test characteristics of AFP, DCP, and AFP-L3 in the detection of HCC
Because patients were followed for variable periods of time, we calculated estimates of sensitivity and specifi city based on three 12-month time periods. Table 4 shows the sensitivity, specificity, positive and negative predictive values, and area under the ROC of biomarker elevations during months 37 -48 in detecting HCC during the same time period and the ensuing 12 months, i.e., from month 37 to month 60 in all patients ( Table 4a ) and in only those with cirrhosis ( Table 4b ). We used cutoff s for DCP and AFP so that we could look at combinations of biomarkers. ROC curves for total AFP and DCP as continuous predictors are shown in Figures 2a (for the entire cohort) and Figure 2b (just those with cirrhosis). In the entire cohort, DCP ≥ 40 mAU / ml had the highest sensitivity, 64 % , but specifi city was only 50 % . AFP ≥ 200 ng / ml, AFP-L3 ≥ 10 % , or a combination of all three biomarkers (AFP ≥ 20 ng / ml, DCP ≥ 40 mAU / ml, and AFP-L3 ≥ 10 % ) had the highest specifi city, ≥ 98 % , but sensitivity varied from 20 to 24 % . AFP ≥ 20 ng / ml had the highest area under the ROC of 0.70, with a sensitivity of 60 % and specifi city of 81 % . Th e negative predictive values of all three biomarkers were high ( ≥ 97 % ), whereas the positive predictive values for individual tests were poor. When individual biomarkers were evaluated, positive predictive value for total AFP ≥ 200 ng / ml was 31 % , for total AFP ≥ 20 ng / ml combined with AFP-L3 ≥ 10 % was 32 % , and for total AFP ≥ 20 ng / ml, AFP-L3 ≥ 10 % , and DCP ≥ 90 mAU / ml was 63 % , but the latter was based on only eight patients ( Table 4a ) . Similar results were observed in those with cirrhosis ( Table 4b ) . Th e sensitivity of biomarker elevations during months 13 -24 or months 25 -36 in detecting HCC in the entire cohort was substantially lower ( Supplementary Table B online), although the specifi city was similar.
DISCUSSION
Th e utility of biomarkers in HCC surveillance remains controversial. For decades, clinicians have relied on AFP for HCC surveillance, but the value of this marker is now doubted ( 10 -13 ) . Two novel tumor markers -AFP-L3 and DCP -proposed to complement or substitute for AFP for the diagnosis of HCC ( 14, 15 ) have been adopted widely in Japan since the late 1990s. Few prospective studies, however, have been done to evaluate the usefulness of these new biomarkers in North American populations ( 33 ) .
Earlier, we reported that AFP elevations identifi ed at the time of routine study visits during the HALT-C Trial were substantially more likely to occur in the absence than in the presence of HCC. Elevation of AFP was not only nonspecifi c but also insensitive as a marker of HCC in our cohort of patients with advanced fi brosis and chronic hepatitis C ( 12 ) , suggesting that the increased levels in such patients refl ect the hepatocellular regeneration (hepatocyte turnover) that occurs in the setting of chronic liver injury and nodular architectural reorganization. Unlike our prior study of baseline AFP ( 12 ) or a nested case -control study that focused on subjects with HCC ( 32 ), this analysis included all and increased fi brosis score, and, unexpectedly, with Mallory bodies detected histologically ( 12 ) . A link between AFP elevation and hepatic infl ammation was reinforced by the reduction in AFP during antiviral therapy ( 12 ) .
AFP has long been used as a screening test for HCC, but because most AFP elevations in chronic hepatitis C are not associated HALT-C subjects followed prospectively. We observed that AFP levels were higher in patients with cirrhosis than in those with bridging fi brosis and correlated with the level of hepatic infl ammation, i.e., increased AST, high AST / ALT ratio, high log serum ferritin, high histologic activity index (grade of hepatic infl ammation), as well as with the degree of fi brosis, i.e., low platelet count with HCC, AFP testing has the potential to generate anxiety for patients and physicians and prompt expensive, sometimes invasive additional tests. Th erefore, improved biomarkers for the detection of HCC command a high priority. Th e HALT-C Trial, which involved patients with advanced chronic hepatitis C followed for a prolonged time period, provided an excellent population in which to assess the test characteristics of AFP and the two novel biomarkers purported to improve the accuracy of HCC detection. In this ancillary study of the prospective HALT-C Trial, we evaluated AFP, DCP, and AFP-L3 as biomarkers for detection of HCC on serial frozen serum samples. Th e two newer biomarkers fared no better than AFP; AFP, DCP, and AFP-L3 elevations were common in patients without HCC and were infl uenced by race, gender, age, and severity of liver disease, and these other patient factors were more likely to account for biomarker elevation than HCC, explaining, in part, the poor performance of these biomarkers in the detection of HCC.
Most prior studies supporting the value of HCC biomarkers in patients with chronic liver disease were cross-sectional in design ( 19, 26, 29, 30, 35 ) . In such cross-sectional studies, the frequency of elevated biomarkers and factors associated with their elevation in patients without HCC have remained poorly defi ned, and the value of these biomarkers in predicting the presence or absence of HCC in patients followed prospectively over time cannot be determined.
To assess the specifi city of total AFP, AFP-L3 % , and DCP as biomarkers of HCC, we examined the levels of these biomarkers over time in 855 patients with chronic HCV infection and advanced fi brosis. In agreement with Nakamura et al. ( 26 ) and Leerapun et al. ( 19 ) , we observed that 25.3 % of HALT-C Trial subjects had a modest elevation of total AFP levels (20 -199 ng / ml), and, like Nguyen et al. ( 35 ) , we found that an AFP value ≥ 200 ng / ml was rare (3.0 % ). Furthermore, in those who had total AFP ≥ 200 ng / ml, HCC was present in only 5 / 16 patients. Identifi ed in our analysis but not reported previously, a ≥ 2-fold increase in total AFP over the average value during the preceding year was observed in 16.8 % . Also, similar to data reported by Marrero et al. ( 29 ) , 11.6 % of subjects in our study without HCC had modestly elevated DCP values (90 -149 mAU / ml), whereas 14.7 % had markedly increased values, ≥ 150 mAU / ml. With regard to AFP-L3, only 9.0 % of subjects without HCC in this study had levels ≥ 10 % , not dissimilar from the frequency reported by the Early Detection Research Network (EDRN) investigators ( 29 ) , but lower than the 15 % frequency among 169 cirrhotic patients without HCC reported by Volk et al ( 30 ) . Because other studies included patients with cirrhosis of a variety of causes, whereas ours was confi ned to patients with chronic hepatitis C, direct comparisons between prior data and ours is diffi cult.
In addition to being associated with the current or future presence of HCC, elevated levels of AFP and of the other biomarkers were more frequent in younger patients, women, blacks, and patients with more advanced fi brosis ( Table 3 ). Nguyen et al. ( 35 ) found that total AFP levels were lower in African Americans than in Caucasians with HCC, and, thus, our contradictory fi nding that being African American was associated independently with increased levels of AFP in those without HCC requires further investigation. Lower AFP levels in patients with HCC and higher AFP levels in those with advanced liver disease but no HCC would make AFP an even less desirable biomarker for HCC surveillance among African Americans with cirrhosis. As was the case for total AFP, one predictor of an increase in DCP was the presence of more advanced liver disease, as demonstrated by low albumin, high international normalized ratio, and high AST / ALT ratio, but, unlike increased AFP levels, an increased DCP level was associated with male gender, suggesting gender diff erences between elevated AFP and DCP. Because elevations of each marker appear to be aff ected by diff erent patient characteristics, biomarkers may be more useful when used in combination ( 28, 32 ) , supported by the observation that 
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
3 The α -fetoprotein (AFP) is the most commonly used biomarker in surveillance for hepatocellular carcinoma (HCC), but its sensitivity and specifi city in detecting HCC is poor.
